Taysha Gene Therapies to Release First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 15

About this update from Taysha Gene Therapies, Inc.

DALLAS , May 08, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that it will report its financial results for the first quarter ended March 31, 2025 , and host a corporate update conference call and webcast on Thursday, May 15, 2025 , at 8:30 AM Eastern Time . Conference Call Details Thursday, May 15 , at 8:30 AM Eastern Time / 7:30 AM Central Time Toll Free: 877-407-0792International: 201-689-8263Conference ID: 13753490Webcast: https://ir.tayshagtx.com/news-events/events-presentations About Taysha Gene Therapies Taysha Gene Therapies (Nasdaq: TSHA) is a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system. Its lead clinical program TSHA-102 is in development for Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. With a singular focus on developing transformative medicines, Taysha aims to address severe unmet medical needs and dramatically improve the lives of patients and their caregivers. The Company’s management team has proven experience in gene therapy development and commercialization. Taysha leverages this experience, its manufacturing process and a clinically and commercially proven AAV9 capsid in an effort to rapidly translate treatments from bench to bedside. For more information, please visit http://www.tayshagtx.com . Company Contact: Hayleigh Collins Senior Director, Corporate Communications and Investor Relations Taysha Gene Therapies, Inc. [email protected] Media Contact: Carolyn Hawley Inizio Evoke [email protected] Source: Taysha Gene Therapies, Inc.

View stock analysis, news, and events for Taysha Gene Therapies, Inc.